EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, Se Hoon Park, Giandomenico Roviello, Ondřej Fiala, Zin W Myint, Jakub Kucharz, Javier Molina-Cerrillo, Daniele Santini, Thomas Buttner, Alexandr Poprach und 19 weitere

Cancer Immunology, Immunotherapy · 04.06.2024 · 73 (8)

DOI: 10.1007/s00262-024-03719-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.06.2024. Verfasst von Lorena Incorvaia und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, 90127, Pal…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune combinations are lacking.

Method

This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with immuno-oncology combinations as first-line therapy.

Results

A total of 1827 mRCC patients from 71 cancer centers in 21 countries were included. The median OS was 38.7 months (95% CI 32.7–44.2) in the overall study population: 40.0 months (95% CI 32.7–51.6) in males and 38.7 months (95% CI 26.4–41.0) in females ( p = 0.202). The median OS was higher in males vs. females in patients aged 18-49y (36.9 months, 95% CI 29.0–51.6, vs. 24.8 months, 95% CI 16.8–40.4, p = 0.426, with + 19% of 2y-OS rate, 72% vs. 53%, p = 0.006), in the clear cell histology subgroup (44.2 months, 95% CI 35.8–55.7, vs. 38.7 months, 95% CI 26.0–41.0, p = 0.047), and in patients with sarcomatoid differentiation (34.4 months, 95% CI 26.4–59.0, vs. 15.3 months, 95% CI 8.9–41.0, p < 0.001). Sex female was an independent negative prognostic factor in the sarcomatoid population (HR 1.72, 95% CI 1.15 − 2.57, p = 0.008).

Conclusions

Although the female’s innate and adaptive immunity has been observed to be more active than the male’s, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50 years of age showed shorter OS than males.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansFemaleMaleMiddle AgedAdultAgedYoung AdultAdolescentSex FactorsImmune Checkpoint InhibitorsPrognosisImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsSurvival RateAged, 80 and over

Stichwörter der Autor:innen

ARON-1 studyGender differencesImmune-based combinationsImmunotherapyNCT05287464Renal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, 90127, Palermo, Italy. lorena.incorvaia@unipa.it.
  • Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil. fsabinocba@gmail.com.
  • Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil. fsabinocba@gmail.com.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea.

Förderung

  • Università degli Studi di Palermo

Zitieren

APA

Incorvaia, L., Monteiro, F. S. M., Massari, F., Park, S. H., Roviello, G., Fiala, O., Myint, Z. W., Kucharz, J., Molina-Cerrillo, J., Santini, D., Buttner, T., Poprach, A., Kopecky, J., Zeppellini, A., Pichler, M., Buchler, T., Pichler, R., Facchini, G., Fay, A. P., …, & Santoni, M. (2024). Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer Immunology, Immunotherapy, 73(8). https://doi.org/10.1007/s00262-024-03719-0

Vancouver

Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, et al. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer Immunology, Immunotherapy. 2024;73(8). doi:10.1007/s00262-024-03719-0

BibTeX
@article{Incorvaia2024,
  author = {Incorvaia, Lorena and Monteiro, Fernando Sabino Marques and Massari, Francesco and Park, Se Hoon and Roviello, Giandomenico and Fiala, Ondřej and Myint, Zin W and Kucharz, Jakub and Molina-Cerrillo, Javier and Santini, Daniele and Buttner, Thomas and Poprach, Alexandr and Kopecky, Jindrich and Zeppellini, Annalisa and Pichler, Martin and Buchler, Tomas and Pichler, Renate and Facchini, Gaetano and Fay, Andre Poisl and Soares, Andrey and Manneh, Ray and Iezzi, Laura and Kuronya, Zsofia and Russo, Antonio and Bourlon, Maria T and Bhuva, Dipen and Ansari, Jawaher and Kanesvaran, Ravindran and Grande, Enrique and Buti, Sebastiano and Santoni, Matteo},
  title = {Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {8},
  doi = {10.1007/s00262-024-03719-0}
}
Kostenlos starten →